Zymeworks (ZYME) & Radius Health (NASDAQ:RDUS) Head to Head Comparison

Radius Health (NASDAQ: RDUS) and Zymeworks (NYSE:ZYME) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Valuation & Earnings

This table compares Radius Health and Zymeworks’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Radius Health N/A N/A -$182.80 million ($5.43) -6.74
Zymeworks $11.00 million 29.72 -$33.80 million N/A N/A

Zymeworks has higher revenue and earnings than Radius Health.

Analyst Ratings

This is a breakdown of current ratings and price targets for Radius Health and Zymeworks, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Radius Health 0 4 6 0 2.60
Zymeworks 2 0 4 0 2.33

Radius Health presently has a consensus target price of $50.75, indicating a potential upside of 38.74%. Zymeworks has a consensus target price of $16.00, indicating a potential upside of 24.22%. Given Radius Health’s stronger consensus rating and higher possible upside, analysts clearly believe Radius Health is more favorable than Zymeworks.

Insider & Institutional Ownership

7.2% of Zymeworks shares are owned by institutional investors. 15.0% of Radius Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


This table compares Radius Health and Zymeworks’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Radius Health N/A -87.19% -68.29%
Zymeworks -1,387.89% -117.85% -54.48%


Radius Health beats Zymeworks on 6 of the 10 factors compared between the two stocks.

Radius Health Company Profile

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.

Zymeworks Company Profile

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company’s lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply